Zusammenfassung
Hintergründe zur Pharmakokinetik und zu Interaktionen werden dargestellt. Alle in der Psychopharmakotherapie relevanten Wechselwirkungen werden in Anhang INT und Anhang SUB so aufgeführt, dass der Leser die einzelnen Risiken selbst nachvollziehen kann. Der Bezug zu den Angaben bei den einzelnen Präparaten wird hergestellt.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Barski OA, Tipparaju SM, Bhatnagar A (2016) The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 40:553–624
Belmonte C, Ochoa D, Román M et al (2018) Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers. Basic Clin Pharmacol Toxicol 122(6):596–605
Deb S, Arrighi S (2021) Potential effects of COVID-19 on cytochrome P450-mediated drug metabolism and disposition in infected patients. Eur J Drug Metab Pharmacokinet 46(2):185–203
Elmeliegy M, Vourvahis M, Guo C, Wang DD (2020) Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug-drug interaction studies. Clin Pharmacokinet 59(6):699–714
Gatti M, Pea F (2022) The cytokine release syndrome and/or the proinflammatory cytokines as underlying mechanisms of downregulation of drug metabolism and drug transport: a systematic review of the clinical pharmacokinetics of victim drugs of this drug-disease interaction under different clinical conditions. Clin Pharmacokinet 61(11):1519–1544
Haen E (2014) Arzneimittelinteraktionen. Nervenarzt 85:417–426
Hefner G, Shams ME, Unterecker S et al (2016) Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels. Psychopharmacology (Berl) 233(9):1695–1705
Herbild L, Andersen SE, Werge T et al (2013) Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs? Basic Clin Pharmacol Toxicol 113(4):266–272
Hicks JK, Swen JJ, Thorn CF et al (2013) Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 93:402–408
Hicks JK, Bishop JR, Sangkuhl K et al (2015) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 98:127–134
Hiemke C (2019) Concentration-effect relationships of psychoactive drugs and the problem to calculate therapeutic reference ranges. Ther Drug Monit 41(2):174–179
Hiemke C, Eckermann G (2014) Kombinationstherapie/Polypharmazie: Interaktionen von Psychopharmaka. Psychopharmakotherapie 21:269–279
Hiemke C, Bergemann N, Clement HW et al (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51:9–62
Jukić MM, Haslemo T, Molden E et al (2018) Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients. Am J Psychiatry 175:463–470
Koehn LM (2020) ABC efflux transporters at blood-central nervous system barriers and their implications for treating spinal cord disorders. Neural Regen Res 15(7):1235–1242
Koonrungsesomboon N, Khatsri R, Wongchompoo P, Teekachunhatean S (2018) The impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysis. Pharmacogenomics J 18(6):760–768
Lenoir C, Terrier J, Gloor Y et al (2021) Impact of SARS-CoV-2 infection (COVID-19) on cytochromes P450 activity assessed by the Geneva cocktail. Clin Pharmacol Ther 110(5):1358–1367
Manikandan P, Nagini S (2018) Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets 19(1):38–54
Milosavljevic F, Bukvic N, Pavlovic Z et al (2021) Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta-analysis. JAMA Psychiatry 78(3):270–280
Moschny N, Hefner G, Grohmann R et al (2021) Therapeutic drug monitoring of second- and third-generation antipsychotics – influence of smoking behavior and inflammation on pharmacokinetics. Pharmaceuticals 14(6):514
Naseri A, Sadigh-Eteghad S, Seyedi-Sahebari S et al (2023) Cognitive effects of individual anticholinergic drugs: a systematic review and meta-analysis. Dement Neuropsychol 17:e20220053
Nicolussi S, Drewe J, Butterweck V, Meyer Zu Schwabedissen HE (2020) Clinical relevance of St. John’s wort drug interactions revisited. Br J Pharmacol 177(6):1212–1226
Oda S, Fukami T, Yokoi T et al (2015) A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. Drug Metab Pharmacokinet 30:30–51
Petri H (2023) Wechselwirkungen von Arzneimitteln mit der Nahrung. Internist Praxis 67:1–13
Piel M, Schmitt U, Bausbacher N et al (2014) Evaluation of P-glycoprotein (abcb1a/b) modulation of [(18)F]fallypride in MicroPET imaging studies. Neuropharmacology 84:152–158
Relling MV, Klein TE, Gammal RS et al (2020) The clinical pharmacogenetics implementation consortium: 10 years later. Clin Pharmacol Ther 107(1):171–175
Saiz-Rodríguez M, Belmonte C, Román M et al (2018) Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants. Basic Clin Pharmacol Toxicol 123(4):474–485
Schoretsanitis G, Kane JM, Correll CU et al (2020) Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry 81(3):19cs13169
Scotton WJ, Hill LJ, Williams AC, Barnes NM (2019) Serotonin ayndrome: pathophysiology, clinical features, management, and potential future directions. Int J Tryptophan Res 12:1178646919873925
Unterecker S, Hefner G, Baumann P et al (2019) Therapeutisches Drug-Monitoring in der Neuropsychopharmakologie: Zusammenfassung der Konsensusleitlinien 2017 der TDM-Arbeitsgruppe der AGNP. Nervenarzt 90(5):463–471
van der Schans J, Hak E, Postma M et al (2019) Effects of pharmacogenetic screening for CYP2D6 among elderly starting therapy with nortriptyline or venlafaxine: a pragmatic randomized controlled trial (CYSCE Trial). J Clin Psychopharmacol 39(6):583–590
van Westrhenen R, Aitchison KJ, Ingelman-Sundberg M, Jukić MM (2020) Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going? Front Psychiatry 11:94
Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–141
Zhou Y, Ingelman-Sundberg M, Lauschke VM (2017) Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther 102(4):688–700
Zubenko GS, Sommer BR, Cohen BM (2018) On the marketing and use of pharmacogenetic tests for psychiatric treatment. JAMA Psychiatry 75(8):769–770
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Hiemke, C., Hefner, G., Benkert, O. (2023). Pharmakokinetik und Arzneimittelinteraktionen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-67685-1_16
Download citation
DOI: https://doi.org/10.1007/978-3-662-67685-1_16
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-67684-4
Online ISBN: 978-3-662-67685-1
eBook Packages: Medicine (German Language)